

References

S-217

1. InterQual Level of Care Criteria 2017. Acute Care Adult. McKesson Health Solutions, LLC.
2. Chen R, Palmer J, Thomas S, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. *Blood*. 2012; 119(26): 6379-6381.
3. Ram-Wolf C, Venon D, Franchi P, et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. *British Journal of Haematology*. 2014; 166: 292–308.
4. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30 hematologic malignancies: The German Hodgkin Study Group experience. *Blood* 2012; 120(7).
5. Carella A. Role of hematopoietic stem cell transplantation in relapsed/refractory Hodgkin Lymphoma. *Mediterranean Journal of Hematology and Infectious Diseases*. 2012; 4(1)e2012059.
6. Czyz A, Dankowska A, Matuszak M, et al. Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma – characteristics and risk factor analysis. *Wspolczesna Onkol*. 2013; 17(2):200-204.
7. Czyz A, Dankowska A, Dytfeld D, et al. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: A single-center experience. *Medical Oncology*. 2013; 30:611-620.
8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hodgkin Lymphoma. Version 2.2014.
9. Cairo M, Woessmann W, Pagel J. Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas. *Biology Blood and Marrow Transplant*. 2013; 19(20):S38-S43.
10. Hahn T, McCarthy P, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin Lymphoma. *Biology of Blood Marrow Transplant*. 2013; 19(12):1740–1744.
11. Neste E, Casasnovas O, André M, et al. Classical Hodgkin's lymphoma: The Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. *Haematologica*. 2013; 98(8):1185–1195.
12. American Cancer Society. High-dose Chemotherapy and Stem Cell Transplant for Hodgkin Lymphoma. 2017.
13. Kako S, Izutsu K, Kato K, et al. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *American Journal of Hematology*. 2015; 90(2):132-138.